Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Modeling of long-term PFS in NDMM treated w/ Dara-VRd on PERSEUS (TE pts) finds 158-255 months (VRd 76-119 mos) while for CEPHEUS (TIE pts) projected median PFS range across distributions was 96-118 (VRd 52-54 mos).”
Title: Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone
Authors: Pieter Sonneveld, Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Philippe Moreau, Hermann Einsele, Mario Boccadoro, Fredrik Borgsten, Andras Borsi, Marjorie Nobrega, Viktor Kovács, Jianping Wang, Melissa Rowe, Anna Sitthi-Amorn, Robin L. Carson, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Saad Z. Usmani
You can read the full article on Journal of Clinical Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
